76 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
3 Large-Cap Stocks Hitting 52-Week Highs: Are They Buys? https://www.fool.com/investing/2019/03/26/3-large-cap-stocks-hitting-52-week-highs-are-they.aspx?source=iedfolrf0000001 Mar 26, 2019 - Can these big high-flying stocks keep the momentum going?
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio http://www.zacks.com/stock/news/366656/why-merck-mrk-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-366656 Mar 29, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Advaxis Up on Positive Early-Stage Immunotherapy Study Data http://www.zacks.com/stock/news/369278/advaxis-up-on-positive-early-stage-immunotherapy-study-data?cid=CS-ZC-FT-369278 Apr 02, 2019 - Advaxis' (ADXS) immunotherapy candidate, ADXS-PSA, achieves favorable overall survival in mCRPC patients in combination with Merck's Keytruda.
Merck's Keytruda Gets Nod for First-Line Lung Cancer in China http://www.zacks.com/stock/news/369336/mercks-keytruda-gets-nod-for-first-line-lung-cancer-in-china?cid=CS-ZC-FT-369336 Apr 02, 2019 - Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting in China.
Aeglea (AGLE) Reports New Positive Data for Pegzilarginase http://www.zacks.com/stock/news/372396/aeglea-agle-reports-new-positive-data-for-pegzilarginase?cid=CS-ZC-FT-372396 Apr 08, 2019 - Aeglea (AGLE) reports new positive data for pegzilarginase in patients with Arginase 1 Deficiency.
AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer http://www.zacks.com/stock/news/377515/astrazeneca-mercks-lynparza-wins-eu-nod-for-breast-cancer?cid=CS-ZC-FT-377515 Apr 10, 2019 - AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for treating HER2-negative locally-advanced/metastatic breast cancer.
Seattle Genetics' Adcetris Progresses Well Amid Competition http://www.zacks.com/stock/news/379195/seattle-genetics-adcetris-progresses-well-amid-competition?cid=CS-ZC-FT-379195 Apr 11, 2019 - Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group http://www.zacks.com/stock/news/379812/mercks-keytruda-gets-fda-nod-for-expanded-lung-cancer-group?cid=CS-ZC-FT-379812 Apr 12, 2019 - Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer http://www.zacks.com/stock/news/380671/jjs-erdafitinib-gets-fda-approval-for-urothelial-cancer?cid=CS-ZC-FT-380671 Apr 15, 2019 - FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Here Are the Key Takeaways From J&J's Q1 Earnings Report http://www.zacks.com/stock/news/386860/here-are-the-key-takeaways-from-jjs-q1-earnings-report?cid=CS-ZC-FT-386860 Apr 18, 2019 - Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.

Pages: 123456...8

Page 1>